Pending FDA Market Clearance for Over-the-Counter Sales We had a second status meeting with the FDA on Wednesday, July 20, 2016. Senior Management from the Neurology and Physical Medicine Group, 4 examiners, the Head of the Physical Medicine, and the project statistician were present. The meeting went well and the tenor was very good. Our … Continue Reading
Your Voice Matters
How is your chronic pain treated? If you feel your illness is misunderstood and you could use better or less costly treatments, sign this petition today asking the White House to implement the National Pain Strategy. The National Fibromyalgia & Chronic Pain Association (NFMCPA), with the Consumer Pain Advocacy Task Force (CPATF), recently launched a … Continue Reading
BioElectronics Company Update – July 22, 2016
Pending U.S. FDA Market Clearance for Over-the-Counter Sales We had a second status meeting with the FDA on Wednesday, July 20, 2016. Senior Management from the Neurology and Physical Medicine Group, 4 examiners, the Head of the Physical Medicine, and the project statistician were present. The meeting went well and the tenor was very good. … Continue Reading
BioElectronics Company Update July 7, 2016
BioElectronics Expands Pulsed Shortwave Technology Thursday, July 7, 2016 Dr. Sree Koneru, our Director of Electroceutical Research working at the Clinical Science and Engineering Research Center, New York State University, Binghamton, New York, has made significant advances in our understanding and development of pulsed shortwave technology. A series of experiments using a unique testing device … Continue Reading
BioElectronics Company Update – June 8, 2016
US FDA Meeting On May 24, 2016, we met with FDA reviewer for our ActiPatch device, key management from the Physical Medicine and Neurotherapeutic Devices Branch, senior leadership from the Division of Neurological and Physical Medicine Devices, and a Regulatory Advisor, Office of Device Evaluation. BioElectronics Attendees: Richard Staelin, PhD, Chairman of Board, PhD in … Continue Reading
BioElectronics Corporation Engages Adam Staelin As Executive Vice President of Sales and Marketing
FREDERICK, Md., May 11, 2016 /PRNewswire/ — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer pain management medical devices, today announced that it has engaged Adam Staelin as the Executive Vice President of Sales and Marketing. Mr. Staelin has 20 years of sales and marketing experience and has held major management roles at Teradata and Valassis. While at Teradata, a … Continue Reading
BioElectronics Responds to U.S. FDA’s Comments on its Market Clearance Application
FREDERICK, Md., May 10, 2016 /PRNewswire/ — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices, announced that it remains in negotiations with the U.S. Food and Drug Administration (“FDA”) regarding its 510(k) premarket notification for the ActiPatch® Musculoskeletal Pain Therapy. Two weeks ago, it submitted detailed responses to the FDA’s questions related to the … Continue Reading
BioElectronics’ Drug-free ActiPatch® Pain Therapy Highlighted in UK’s Express Newspaper on Dangers of Excessive Drug Use
FREDERICK, Md., April 28, 2016 /PRNewswire/ — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its drug-free ActiPatch® product was noted in the United Kingdom’s Express Newspaper Health Section, http://www.express.co.uk/life-style/health/664330/arthritis-pain-pills-warning-sufferers-taking-too-many-drugs-fight-agony. The paper has a circulation of 400,000 that will increase the awareness of ActiPatch therapy for arthritis and chronic pain. The … Continue Reading
BioElectronics’ ActiPatch® Chronic Pain Therapy Featured In UK’s Leading Daily Mail Newspaper Health Section
BioElectronics’ ActiPatch® Chronic Pain Therapy Featured In UK’s Leading Daily Mail Newspaper Health Section FREDERICK, MD, USA, March 29, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, announces that its ActiPatch® product’s were featured in the United Kingdom’s leading Daily Mail’s Sunday Health Section, http://www.dailymail.co.uk/health/article-3555221/The-20-pulsing-skin-patch-end-misery-chronic-pain-arthritis-sufferers-diabetics.html. … Continue Reading
BioElectronics President Interviewed by the StockRadio.com
Discusses Bioelectronics Mitigation of Chronic Pain and Drug Use BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced nonprescription $30.00 neuromodulation pain management medical devices, is pleased to release an interview with President, Andy Whelan. The interview can be heard at http://thestockradio.com/andrew-whelan-bioelectronics-corp-biel-2953.html Mr. Whelan explained the science of bioelectronics, the chronic pain market, the far-reaching … Continue Reading